8.5% of analyzed samples had an IDH1 mutation at the R132 residue (mutated to either cysteine, histidine, or serine), which is also the site of the overwhelming majority of somatic IDH mutations in glioma (1, 34). Here, IDH1 is linked to central nervous system cancer.